AIM Will Launch Value and Biotech Funds

AIM Management plans to open a mid-cap value fund and a global biotechnology fund, according to filings with the Securities and Exchange Commission. AIM, which is owned by Amvescap Plc, has about 90 funds and $171 billion in assets under management.

Subscribe Now

Access to premium content including in-depth coverage of mutual funds, hedge funds, 401(K)s, 529 plans, and more.

3-Week Free Trial

Insight and analysis into the management, marketing, operations and technology of the asset management industry.